Loading...

IKNA IKENA ONCOLOGY INC Company Mergers 8-K Filing

KN N

KN

IKENA ONCOLOGY INC

(IKNA)

2025 8-K

Show Summary

Summary

Merger of Equals

Merger of Equals

Merger of Equals

Merger Agreement

Appointment of Chief Operat...

Annual Meeting of Stockholders

Discontinuation of Clinical...

Resignation of Chief Medica...

Financial Results and Workf...

Financial Results and Clini...

Special Meeting Approval

Merger Agreement

Delisting Notice

Annual Meeting of Stockholders

Underwriting Agreement for ...

Preclinical Data Announcement

External Links:

On July 1, 2025, Ikena Oncology announced that Inmagene successfully dosed the first patient in a Phase 2b trial for its drug IMG-007 targeting moderate-to-severe atopic dermatitis, following a merger agreement made on December 23, 2024.

AI Assistant

IKENA ONCOLOGY INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.